Posts

Posted on

LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail

LabCorp Receives FDA Authorization to Make At-Home COVID-19 Collection Kits Available Through Retail

Pixel by LabCorp™ COVID-19 Test Home Collection Kit is first to receive FDA authorization for over-the-counter purchase

BURLINGTON, N.C.–(BUSINESS WIRE)–
LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the Pixel by LabCorp™ COVID-19 Test Home Collection Kit to become the first to be available over the counter without requiring a prescription. The kit is currently available through the Pixel by LabCorp website, and this approval will enable LabCorp to potentially distribute the kit through retail channels.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209006036/en/

Photo courtesy of LabCorp (Photo: Business Wire)

Photo courtesy of LabCorp (Photo: Business Wire)

This authorization is the latest example of LabCorp’s commitment to increase access to COVID-19 testing. The kit allows consumers to self-collect their sample in the privacy of their own home, which helps minimize transmission of the virus. Users then send the sample for processing at LabCorp.

“With the first over-the-counter at-home collection kit ever authorized by the FDA for COVID-19, we are empowering people to learn about their health and make confident decisions,” said Dr. Brian Caveney, chief medical officer and president of LabCorp Diagnostics. “With this authorization, we can help more people get tested, reduce the spread of the virus and improve the health of our communities.”

Upon purchase, users register their Pixel by LabCorp COVID-19 collection kit at the Pixel by LabCorp website and follow the instructions included. Test results are securely delivered to the consumer via the Pixel by LabCorp portal. A healthcare provider will counsel consumers who test positive to assist with healthcare treatment and actions. The Pixel by LabCorp COVID-19 collection kit is not a substitute for visits to a healthcare professional and is for use in adults 18 and older.

Retailers interested in selling Pixel by LabCorp COVID-19 collection kits can contact the company at [email protected].

LabCorp’s COVID-19 PCR test has not been FDA cleared or approved, has been authorized by FDA under an Emergency Use Authorization (EUA), and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019. To learn more about LabCorp, visit www.LabCorp.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing and the potential benefits of a COVID-19 test home collection kit and our responses to and the expected future impacts of the COVID-19 pandemic and the opportunities or future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.

###

LabCorp Contacts:

Media: Chris Allman-Bradshaw – 336-436-8263

[email protected]

Investors: Clarissa Willett – 336-436-5076

[email protected]

KEYWORDS: North Carolina United States North America

INDUSTRY KEYWORDS: Men Medical Devices Infectious Diseases Hospitals Family Genetics Consumer Clinical Trials Cardiology Diabetes Biotechnology AIDS Health Women Pharmaceutical Seniors Oncology

MEDIA:

Logo
Logo
Photo
Photo
Photo courtesy of LabCorp (Photo: Business Wire)
Posted on

DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

DEADLINE MONDAY ALERT: The Schall Law Firm Announces it is Investigating Claims Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm

LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. (“Reata” or “the Company”) (NASDAQ: RETA) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Reata failed to produce MOXIe Part 2 study results sufficient to support marketing approval for omaveloxolone for the treatment of FA from the FDA without additional evidence. It was foreseeable that the FDA would not approve omaveloxolone for the treatment of FA based on the MOXIe Part 2 study alone. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Reata, investors suffered damages.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at [email protected].

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

The Schall Law Firm

Brian Schall, Esq.

310-301-3335

[email protected]

www.schallfirm.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Realty Income Prices $725 Million Of Dual-Tranche Senior Unsecured Notes

PR Newswire

SAN DIEGO, Dec. 9, 2020 /PRNewswire/ — Realty Income Corporation (Realty Income, NYSE: O), The Monthly Dividend Company®, today announced the pricing of a public offering of $325 million of 0.75% senior unsecured notes due March 15, 2026 (the “2026 Notes”) and $400 million of 1.80% senior unsecured notes due March 15, 2033 (the “2033 Notes”). The public offering price for the 2026 Notes was 99.192% of the principal amount for an effective yield to maturity of 0.908% and the public offering price for the 2033 Notes was 98.470% of the principal amount for an effective yield to maturity of 1.941%.

Combined, the new issues of the 2026 Notes and 2033 Notes have a weighted average term of 9.1 years and a weighted average effective yield to maturity of 1.478%. The net proceeds from this offering will be used, along with available cash and additional borrowings, as necessary, to redeem all $950 million aggregate principal amount of the company’s outstanding 3.25% notes due 2022 at the applicable redemption price, plus accrued interest, and/or to use net proceeds for general corporate purposes, which may include acquisitions, improvements of existing properties and/or repayment of borrowings under our $3.0 billion revolving credit facility and/or our $1.0 billion commercial paper program. This offering is expected to close on December 14, 2020, subject to the satisfaction of customary closing conditions.

The active joint book-running managers for the offering are Wells Fargo Securities, Citigroup, J.P. Morgan and TD Securities.

A copy of the prospectus supplement and prospectus, when available, related to this offering may be obtained by contacting: Wells Fargo Securities, 608 2nd Avenue South, Suite 1000, Minneapolis, MN 55402, Attention: WFS Customer Service, by telephone at (800) 645-3751 or by email at [email protected]; Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146 or by email at [email protected]; J.P. Morgan, 383 Madison Avenue, New York, New York 10179, Attention: Investment Grade Syndicate Desk – 3rd floor, by  telephone at (212) 834-4533; or TD Securities, 31 West 52nd Street, 2nd Floor, New York, New York 10019, Attention: Syndicate Department, by telephone at (855) 495-9846.

These securities are offered pursuant to a Registration Statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus included in the Registration Statement and the prospectus supplement related to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction where, or to any person to whom, the offer, solicitation, or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

Statements in this press release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known and unknown risks, which may cause the company’s actual future results to differ materially from expected results. These risks include, among others, general economic conditions, domestic and foreign real estate conditions, tenant financial health, the availability of capital to finance planned growth, volatility and uncertainty in the credit markets and broader financial markets, changes in foreign currency exchange rates, property acquisitions and the timing of these acquisitions, charges for property impairments, the effects of the COVID-19 pandemic and the measures taken to limit its impact, the effects of pandemics or global outbreaks of contagious diseases or fear of such outbreaks, the company’s tenants’ ability to adequately manage its properties and fulfill their respective lease obligations to the company, and the outcome of any legal proceedings to which the company is a party, as described in the company’s filings with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as reflections of the company’s current operating plans and estimates. Actual operating results may differ materially from what is expressed or forecast in this press release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date these statements were made.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/realty-income-prices-725-million-of-dual-tranche-senior-unsecured-notes-301189925.html

SOURCE Realty Income Corporation

Posted on

Immutep’s Chinese Partner EOC Pharma to Start Phase II Metastatic Breast Cancer Study

  • New randomised, double-blind, placebo-controlled phase II clinical study to commence in Q1 CY2021
  • Evaluates the efficacy and safety of eftilagimod alpha in combination with paclitaxel chemotherapy, compared to placebo plus paclitaxel (as per AIPAC study)
  • Fully funded by EOC Pharma, trial will involve approx. 152 patients across 20 clinical trial sites in China
  • Follows encouraging data from Immutep’s ongoing AIPAC Phase IIb study announced end of March and today and presented at the San Antonio Breast Cancer Symposium
  • Global webinar: 11 December at 8.30 am Australian Easter Daylight Time, details below

Sydney, AUSTRALIA, Dec. 10, 2020 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China.

Similar to Immutep’s AIPAC study, the EOC Pharma trial will be a randomised, double-blind, placebo-controlled phase II clinical study with the study endpoints including progression free survival, overall survival and overall response rate. It is expected take place across 20 clinical trial sites in China over 24 months and will evaluate Immutep’s lead product candidate eftilagimod alpha (“efti”, designated EOC202 in China) in combination with paclitaxel in HER2-negative/HR positive metastatic breast cancer patients who have progression after endocrine therapy.

EOC Pharma has received positive scientific advice from the Chinese competent authority, the Chinese National Medical Products Administration, enabling the first patient in to be enrolled and dosed in the trial in Q1 of calendar year 2021.

EOC Pharma CEO, Xiaoming Zou, said: “Breast cancer is now the most common cancer in Chinese women, with more than 1.6 million people being diagnosed and 1.2 million people dying of the disease each year1. It is very important that we find new ways to enhance paclitaxel chemotherapy which continues to be a standard of care for HER2-negative/HR positive metastatic breast cancer patients. Immutep’s recent encouraging interim AIPAC results give us hope we can boost the body’s immune system to deliver better outcomes to patients.”

Immutep CEO Marc Voigt said: “EOC Pharma shares our growing excitement about the potential for the combination of efti with paclitaxel chemotherapy in metastatic breast cancer. Our ongoing AIPAC study evaluating the same combination is already reporting very encouraging data, including a statistically significant survival benefit of 7.1 months in patients under 65 years of age and 9.4 months for patients with a low starting monocyte count. EOC Pharma’s new trial in China brings this innovative new treatment much closer to market for metastatic breast cancer patients.”

EOC Pharma is the exclusive licensee of efti from Immutep for the Chinese market. Under its agreement with Immutep, it will make further milestone payments to the Company if efti achieves specific development milestones as well as undisclosed royalties on sales and is also required to fund the Chinese development of efti.

Webcast Details

Immutep will discuss the recent AIPAC data in a global webcast for investors. Details are as follows:

Date & Time:      Friday 11 December at 8.30 am Australian Eastern Daylight Time (AEDT)
Register:            http://public.viavid.com/index.php?id=142664
Questions:         Investors are invited to submit questions in advance via [email protected].

A replay of the webcast will also be available at www.immutep.com from the day after the event.

About EOC Pharma

EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development and commercialization of innovative oncology products. With an insight-driven strategy and integrated business platform, EOC Pharma strives to build a portfolio of products with strategic synergies from independent R&D and licensing and enrich the product pipeline with first- and best -in-class oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; [email protected]

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]

1 Fan, Lei & Strasser-Weippl, Kathrin & Li, Jun-Jie & Louis, Jessica & Finkelstein, Dianne & Yu, Ke-Da & Chen, Wan-Qing & Zhao, Naiqing & Goss, Prof. (2014). Breast cancer in China. The lancet oncology. 15. e279-e289. 10.1016/S1470-2045(13)70567-9.



Posted on

Meso Numismatics Eliminates All Convertible Debt In Renegotiation Deal and Files 10K

LAS VEGAS, NV, Dec. 09, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean, announced today that “the Company has successfully Eliminated All Convertible Debt In Renegotiation Deal and Files 10K.”

Meso announces that it has renegotiated the consolidation of all its convertible debt into non-convertible promissory notes and warrants. The renegotiation deal effectively saves the company from hundreds of millions of shares of possible dilution.

“We are very pleased that we have been able to renegotiate our convertible debt,” said David Christensen, President and CEO. “Moving forward, the company will seek minimally dilutive sources of capital.”

The company is working on its remaining filings in order to become current.  For more details please read this press release in conjunction with the company’s 10K filed today including the subsequent events note in the financial statements section.

This press release should be read in conjunction with all other filings on www.sec.gov

For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging numismatic and technology company specialized in the Meso Region, including Central America and the Caribbean. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world. With the Company’s breadth of business experience and technology team, the Company will continue to help companies grow.

Forward Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, “forecast”, “anticipates”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact:

[email protected]

Telephone: (800) 956-3935



Posted on

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Splunk Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – SPLK

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Splunk Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – SPLK

NEW YORK–(BUSINESS WIRE)–
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Splunk Inc. (NASDAQ: SPLK) between October 21, 2020 and December 2, 2020, inclusive (the “Class Period”), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Splunk investors under the federal securities laws.

To join the Splunk class action, go to http://www.rosenlegal.com/cases-register-2000.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 2, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-2000.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORDS: China United States North America Asia Pacific New York

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo
Posted on

Flowers Foods Names Heeth Varnedoe Chief Transformation Officer

PR Newswire

THOMASVILLE, Ga., Dec. 9, 2020 /PRNewswire/ — Flowers Foods, Inc. (NYSE: FLO), producer of Nature’s Own, Dave’s Killer Bread, Wonder, Tastykake, and other bakery foods, today announced that Heeth Varnedoe, senior vice president of DSD Regions/Sales, has been promoted to chief transformation officer (CTO), a newly created role at the company, effective January 4, 2021.

As CTO, Varnedoe will be responsible for overseeing the implementation of key, cross-functional initiatives that advance Flowers’ long-term strategic plans. One area of immediate focus for Varnedoe is Flowers’ digital and enterprise resource planning initiative. This is a newly launched, multi-year effort to transform the company’s organizational capabilities, implement new technologies, and make data-driven decisions. Varnedoe will report to Ryals McMullian, president and chief executive officer.

“The creation of a transformation office puts fresh emphasis on transparency, collaboration, and new ways of working at Flowers and allows us to ensure that initiatives are effectively meeting their planned operating and financial goals,” McMullian said. “Heeth was a clear choice for this important position. Not only has he demonstrated strong leadership managing our portfolio optimization work, but he’s also been a champion of the evolutionary steps our company has been taking over the past few years and has a deep understanding and experience of Flowers’ sales and operations.”

Varnedoe joined Flowers Foods in 1990, holding a number of management positions, including president of the company’s bakery in Jacksonville, Florida. He left Flowers in 2000 to pursue other business interests and rejoined in 2012 as vice president of national accounts. In 2016, he was promoted to president of the company’s Phoenix, Arizona bakery and was named to his current role in 2017.


About Flowers Foods

Headquartered in Thomasville, Ga., Flowers Foods, Inc. (NYSE: FLO) is one of the largest producers of packaged bakery foods in the United States with 2019 sales of $4.1 billion. Flowers operates bakeries across the country that produce a wide range of bakery products. Among the company’s top brands are Nature’s Own, Dave’s Killer Bread, Wonder, and Tastykake. Learn more at www.flowersfoods.com.

FLO-CORP


Forward-Looking Statements

Statements contained in this press release that are not historical facts are forward-looking statements. Forward-looking statements relate to current expectations regarding our future financial condition, performance and results of operations and the ultimate impact of the novel strain of coronavirus (COVID-19) pandemic on our business, results of operations and financial condition, planned capital expenditures, long-term objectives of management, supply and demand, pricing trends and market forces, and integration plans and expected benefits of transactions and are often identified by the use of words and phrases such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “should,” “will,” “would,” “is likely to,” “is expected to” or “will continue,” or the negative of these terms or other comparable terminology. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from those projected. Other factors that may cause actual results to differ from the forward-looking statements contained in this release and that may affect the company’s prospects in general include, but are not limited to, (a) the ultimate impact of the COVID-19 pandemic and measures taken in response thereto, including, among other things, temporary or ongoing bakery closures, on our business, results of operations and financial condition, which are highly uncertain and are difficult to predict, (b) general economic and business conditions and the competitive conditions in the baked foods industry, including promotional and price competition, (c) changes in consumer demand for our products, including changes in consumer behavior, trends and preferences, including health and whole grain trends, and the movement toward more inexpensive store-branded products, (d) the success of productivity improvements and new product introductions, (e) a significant reduction in business with any of our major customers including a reduction from adverse developments in any of our customer’s business, (f) fluctuations in commodity pricing, (g) energy and raw material costs and availability and hedging and counterparty risk, (h) our ability to fully integrate recent acquisitions into our business, (i) our ability to achieve cash flow from capital expenditures and acquisitions and the availability of new acquisitions that build shareholder value, (j) our ability to successfully implement our business strategies, including those strategies the company has initiated under Project Centennial, which may involve, among other things, the deployment of new systems and technology and an enhanced organizational structure; (k) our ability to integrate recent acquisitions or the acquisition or disposition of assets at presently targeted values, (l) consolidation within the baking industry and related industries, (m) disruptions in our direct-store delivery system, including litigation or an adverse ruling from a court or regulatory or government body that could affect the independent contractor classification of our independent distributors, (n) increasing legal complexity and legal proceedings that we are or may become subject to, (o) product recalls or safety concerns related to our products, and (p) the failure of our information technology systems to perform adequately, including any interruptions, intrusions or security breaches of such systems or risks associated with the planned implementation of a new enterprise resource planning system. The foregoing list of important factors does not include all such factors, nor necessarily present them in order of importance. In addition, you should consult other public disclosures made by the company, including the risk factors included in our most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) and disclosures made in other filings with the SEC and company press releases, for other factors that may cause actual results to differ materially from those projected by the company. We caution you not to place undue reliance on forward-looking statements, as they speak only as of the date made and are inherently uncertain. The company undertakes no obligation to publicly revise or update such statements, except as required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flowers-foods-names-heeth-varnedoe-chief-transformation-officer-301189910.html

SOURCE Flowers Foods, Inc.

Posted on

Hydrofarm Holdings Group Announces Pricing of Initial Public Offering

PETALUMA, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm”), a leading independent branded hydroponics company with a comprehensive distribution platform, today announced the pricing of its initial public offering of 8,666,667 shares of common stock at a price to the public of $20.00 per share. In addition, Hydrofarm has granted the underwriters a 30-day option to purchase up to an additional 1,300,000 shares to cover over-allotments, if any. The shares are expected to begin trading on December 10, 2020 on the Nasdaq Global Select Market under the ticker symbol “HYFM.” The closing of the offering is expected to occur on December 14, 2020, subject to customary closing conditions.

J.P. Morgan and Stifel are acting as lead book-running managers for the offering and as representatives of the underwriters. Deutsche Bank Securities, Truist Securities and William Blair are acting as book-running managers for the offering.

The offering is being made only by means of a prospectus. Copies of the prospectus, when available, may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at [email protected] or by telephone at (866) 803-9204; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at [email protected].

A registration statement on Form S-1 relating to these securities was declared effective by the Securities and Exchange Commission on December 9, 2020. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Hydrofarm Holdings Group, Inc.

Hydrofarm is a leading independent distributor and manufacturer of hydroponics equipment and supplies for controlled environment agriculture, including high-intensity grow lights, climate control solutions, and growing media, as well as a broad portfolio of innovative and proprietary branded products. For over 40 years, Hydrofarm has helped growers make growing easier and more productive. The Company’s mission is to empower growers, farmers and cultivators with products that enable greater quality, efficiency, consistency and speed in their grow projects. For additional information, please visit: www.hydrofarm.com.

Contacts:

Media Contact

Cory Ziskind / ICR
(646) 277-1232
[email protected]

Investor Contact

Fitzhugh Taylor / ICR
[email protected]



Posted on

ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders

WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting location.

Due to the COVID-19 pandemic, seating capacity will be limited to comply with guidelines promulgated by relevant public health authorities. Social distancing will be observed at all times during the meeting and each attendee will be required to wear a protective face covering. Should more participants want to join the meeting than available seating capacity, those participants will be provided the opportunity participate in the meeting via remote means.

Further information regarding the annual meeting matters is available in the company’s Notice of 2020 Annual Meeting and Proxy Statement filed on October 28, 2020, which is available by clicking on “SEC Filings” under the “Investors” tab on the company’s website.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing GencaroTM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential pharmacogenetic treatment for atrial fibrillation in patients with heart failure. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding
potential
future
development plans for
AB201
, the
expected features and characteristics of
AB201
,
AB201’
s potential to treat
COVID-19
,
or
any other RNA virus associated disease
,
and
future treatment options for patients with
COVID-19
.
Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements;
ARCA
may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of
AB201
or t
o otherwise continue
operations in the future;
results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended
December
 
31
,
 
201
9
, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:

Derek Cole
720.940.2163
[email protected]



Posted on

5-DAY LOOP DEADLINE: Hagens Berman, National Trial Attorneys, Alerts Loop Industries (NASDAQ: LOOP) Investors to Coca-Cola Contract Termination & December 14th Application Deadline, Encourages Investors with Losses to Contact the Firm

PR Newswire

SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ — Hagens Berman urges Loop Industries, Inc. (NASDAQ: LOOP) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have sufficient losses to move for lead plaintiff.

Class Period: Sept. 24, 2018 – Oct. 12, 2020
Lead Plaintiff Deadline: Dec. 14, 2020
Visit: www.hbsslaw.com/investor-fraud/LOOP
Contact An Attorney Now: [email protected]
                                              844-916-0895

Loop (LOOP) Securities Fraud Class Action:

The complaint alleges that Loop made false and misleading statements about its purportedly “proven” technology that breaks down PET plastic to its base chemicals at a recovery rate of 100%. The complaint also alleges that Loop misrepresented its partnerships with key customers, including Coca-Cola.

Investors allegedly began to learn the truth on Oct. 13, 2020, when Hindenburg Research published a report concluding “Loop is smoke and mirrors with no viable technology.” Hindenburg reported that: (i) Loop’s technology is no more efficient or cost effective than traditional PET recycling methods and its previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were “‘technically and industrially impossible;'” (ii) under pressure from CEO Daniel Solomita, Loop’s scientists were tacitly encouraged to lie about the results of the Company’s process internally; and (iii) the Indorama partnership has not even been finalized, and the Thyssenkrupp partnership is on indefinite hold. 

Following Hindenburg‘s report, the price of Loop shares crashed on Oct. 13, 2020.

Then, on Nov. 4, 2020 Loop announced Coca-Cola Cross Enterprise Procurement Group terminated its agreement because “the Company did not satisfy its first production milestone from the joint venture facility by July 2020” as required by the agreement.

“We’re focused on investors’ losses and proving Loop misrepresented its technological capabilities,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a Loop Industries investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Loop Industries should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email mailto:[email protected].


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/5-day-loop-deadline-hagens-berman-national-trial-attorneys-alerts-loop-industries-nasdaq-loop-investors-to-coca-cola-contract-termination–december-14th-application-deadline-encourages-investors-with-losses-to-contact-the–301189851.html

SOURCE Hagens Berman Sobol Shapiro LLP